Raleigh-Durham-Chapel Hill Area
A purpose-driven leader with the vision, experience, and drive to deliver innovation to the market. A passion for building high-performing teams and cultures that deliver results. Proven track record of achieving strategic, financial, and operational goals, in large and small company environments, and across all stages of the product life cycle. Summary • Over 20 years of experience building and leading commercial organizations. • Leadership spanning all commercial functions: Sales, Marketing, Training, Market Access, and BD. • Responsible for all stages of the product life-cycle: pipelines, launches, in-line brands, LOE. • Large and small company environments: market capitalizations ranging from $400M - $200B. • Broad range of therapeutic areas: hematology, oncology, respiratory, metabolic, neurology, and immuno. • Multiple global leadership roles: Global Medicine Development Team and Global Market Access Team. Highlights • P&L responsibility for products and portfolios ranging from $30M to $3B in revenue. • 15+ product launches spanning rare diseases, oncology, and primary care markets. • 10+ years of experience with rare/ultra-rare disease medicines: cell & gene therapy, ERT, and biologics. • Corporate development and commercial diligence, including $900M company acquisition. • Designed and implemented multiple commercial builds, including teams of 500+.
Source and evaluate investment opportunities, and provide operational support to portfolio companies to drive long-term value creation. ARCHIMED is a leading global private equity firm focused on small- and mid-cap healthcare buyouts, with €9B in assets under management.
Served as an embedded strategic advisor to ARCHIMED’s investment team, contributing commercial insight to deal sourcing and diligence.
Support Duke University’s venture investment arm through venture and growth equity investments. Portfolio companies have raised $19.3B+, surpassed $90.7B in enterprise value, and delivered 11 exits, including four in FY25.
Drive vision, growth, and partnerships for a boutique advisory and investment firm translating pioneering science into impact. Invest across healthcare and adjacent areas, and advise public and private companies globally on organizational, commercialization, and corporate development strategy.
Spearheaded the strategic direction for accelerating the development and commercialization of a diverse portfolio of small interfering RNA (siRNA) therapies. Delivered comprehensive commercial insight across all product life cycle stages, ensuring strategic alignment with market demands and maximizing product value.
Led commercialization efforts for a portfolio of autologous ex vivo HSC gene therapies as General Manager, reporting directly to the CEO. Pioneered launch planning, streamlined business operations, and ensured cross-functional execution to foster operational excellence. Unforeseen regulatory challenges resulted in a global restructuring and elimination of U.S. commercialization efforts.